The DOI matches its Crossref record.
Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial
Open accessAbstract
BACKGROUND: Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids. METHODS: We did a pragmatic, multicentre, parallel-group randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3-9, 10-30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted during weeks 1-3. The non-inferiority primary effectiveness outcome was the proportion of participants with three or fewer blisters at 6 weeks. We assumed that doxycycline would be 25% less effective than corticosteroids with a 37% acceptable margin of non-inferiority. The primary safety outcome was the proportion with severe, life-threatening, or fatal (grade 3-5) treatment-related adverse events by 52 weeks. Analysis (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol for non-inferiority effectiveness analysis) used a regression model adjusting for baseline disease severity, age, and Karnofsky score, with missing data imputed. The trial is registered at ISRCTN, number ISRCTN13704604. FINDINGS: Between March 1, 2009, and Oct 31, 2013, 132 patients were randomly assigned to doxycycline and 121 to prednisolone from 54 UK and seven German dermatology centres. Mean age was 77·7 years (SD 9·7) and 173 (68%) of 253 patients had moderate-to-severe baseline disease. For those starting doxycycline, 83 (74%) of 112 patients had three or fewer blisters at 6 weeks compared with 92 (91%) of 101 patients on prednisolone, an adjusted difference of 18·6% (90% CI 11·1-26·1) favouring prednisolone (upper limit of 90% CI, 26·1%, within the predefined 37% margin). Related severe, life-threatening, and fatal events at 52 weeks were 18% (22 of 121) for those starting doxycycline and 36% (41 of 113) for prednisolone (mITT), an adjusted difference of 19·0% (95% CI 7·9-30·1), p=0·001. INTERPRETATION: Starting patients on doxycycline is non-inferior to standard treatment with oral prednisolone for short-term blister control in bullous pemphigoid and significantly safer in the long-term. FUNDING: NIHR Health Technology Assessment Programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Borradori, L., Van Beek, N., Feliciani, C., Tedbirt, B., Antiga, E., Bergman, R., Böckle, B. C., Caproni, M., Caux, F., Chandran, N. S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18220 · Cited by 277
Self-citationUnmet medical needs in chronic, non-communicable inflammatory skin diseases
Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875492 · Cited by 158
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Understanding CD4+ T cells in autoimmune bullous diseases
Lee, A. Y., Kim, T., & Kim, J. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161927 · Cited by 13
Metadata
- Authors
- Williams, H. C., Wojnarowska, F., Kirtschig, G., Mason, J., Godec, T. R., Schmidt, E., Chalmers, J. R., Childs, M., Walton, S., Harman, K., Chapman, A., Whitham, D., Nunn, A. J., Adams, J., Akhras, V, Anstey, A., Barnard, C., Bell, H., Blackford, S., Bröcker, E., Carmichael, A., Coelho, R. R., Craig, F., Davies, K., Ellis, R., English, J., Gläser, R., Groves, R., Günthert, C., Hampton, P. J., Hepburn, N., Hügel, R., Hussain, K., Ingram, J., Layton, A. M., Levell, N. J., Lewis, V, Malhomme, H., Omerod, A., Patel, G., Rallan, R., Ravenscroft, J., Santander, H., Steinbrink, K., Sticherling, M., Thomas, C., Vatve, M., van Beek, N., Venning, V, Veysey, E., Wachsmuth, R., Wahie, S., Walker, B., Walsh, M., Wee, J., Westmoreland, M., Wong, G., Ferguson, A., Verpetinske, I., Duarte-Williamson, E., Antony, F., Bower, C., Gawkrodger, D., Taghipour, K., Dunnill, M. G. S., Waters, A., Bottomley, W., Wright, A., Sterling, J., Azam, A., Gibbs, S., Luger, T., Salvary, I., Lovell, C., Ilchyshyn, A., Gibbon, K., Nik, M., Charles-Holmes, R., & Lavery, A. L.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 389
- Issue
- 10079
- Pages
- 1630-1638
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2575603189
- Cited by
- 226
- References
- 0
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)30560-3
- The paper
- Williams, H. C., Wojnarowska, F., Kirtschig, G., Mason, J., Godec, T. R., Schmidt, E., Chalmers, J. R., Childs, M., Walton, S., Harman, K., Chapman, A., Whitham, D., Nunn, A. J., Adams, J., Akhras, V, Anstey, A., Barnard, C., Bell, H., Blackford, S., . . . Lavery, A. L. (2017). Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)30560-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.